Ken Griffin Silverback Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	N/A	-17,500 Reduced 87.06%	2,600 $0
Q2 2024 Aug 14, 2024	SELL	N/A	-5,100 Reduced 20.24%	20,100 $0
Q1 2024 May 15, 2024	SELL	N/A	-6,800 Reduced 21.25%	25,200 $0
Q4 2023 Feb 14, 2024	SELL	N/A	-17,100 Reduced 34.83%	32,000 $0
Q3 2023 Nov 14, 2023	BUY	N/A	9,100 Added 22.75%	49,100 $0
Q2 2023 Aug 14, 2023	BUY	N/A	2,400 Added 6.38%	40,000 $0
Q1 2023 May 15, 2023	SELL	N/A	-2,000 Reduced 5.05%	37,600 $0
Q4 2022 Feb 14, 2023	BUY	$0.0 - $6.07 $0 - $166,318	27,400 Added 224.59%	39,600 $0
Q3 2022 Nov 14, 2022	SELL	$3.91 - $5.52 $191,981 - $271,032	-49,100 Reduced 80.1%	12,200 $64,000

163

62.7M

872K

589K

Ticker SBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,473,800
Description
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.